| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2005 | WO2005009451A1 Bacteriophage-containing therapeutic agents |
| 02/03/2005 | WO2005009447A1 Single dose fast dissolving azithromycin |
| 02/03/2005 | WO2005009446A1 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2005009444A1 Medicinal compositions |
| 02/03/2005 | WO2005009442A1 Nasal pharmaceutical composition of piribedil |
| 02/03/2005 | WO2005009441A1 High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
| 02/03/2005 | WO2005009438A1 Nicotinamide compounds useful as pde4 inhibitors |
| 02/03/2005 | WO2005009437A1 Design and synthesis of optimized ligands for ppar |
| 02/03/2005 | WO2005009436A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | WO2005009434A2 Compounds and methods for inducing apoptosis in cancer cells |
| 02/03/2005 | WO2005009433A1 Use of 3,5 diiodothyronine as regulators of lipid metabolism |
| 02/03/2005 | WO2005009432A1 New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith |
| 02/03/2005 | WO2005009431A1 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| 02/03/2005 | WO2005009430A1 Compounds useful for treating neurological disorders |
| 02/03/2005 | WO2005009429A1 Compositions containing prodrugs of florfenicol and methods of use |
| 02/03/2005 | WO2005009428A2 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 02/03/2005 | WO2005009427A1 Curative medicine for allergosis |
| 02/03/2005 | WO2005009426A1 Treatment of heaves |
| 02/03/2005 | WO2005009425A1 Substituted 2-aminotetralin for the treatment of depression |
| 02/03/2005 | WO2005009424A1 Use of rotigotine for the treatment of depression |
| 02/03/2005 | WO2005009423A1 Necrosis avid tracer agent |
| 02/03/2005 | WO2005009422A1 Anti-inflammatory formulations |
| 02/03/2005 | WO2005009421A2 The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| 02/03/2005 | WO2005009420A2 Pharmaceutical compositions of short-acting sedative hypnotic agent |
| 02/03/2005 | WO2005009419A2 Use of 5-methoxytryptamine as a cardioprotective agents |
| 02/03/2005 | WO2005009418A2 Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| 02/03/2005 | WO2005009416A1 Modified release compositions for minocycline |
| 02/03/2005 | WO2005009414A1 Sutained release formulation for venlafaxine hydrochloride |
| 02/03/2005 | WO2005009411A2 Particles containing an active agent in the form of a co-precipitate |
| 02/03/2005 | WO2005009410A2 Pharmaceutical compositions having a swellable coating |
| 02/03/2005 | WO2005009407A2 Oral pharmaceutical formulations of olanzapine |
| 02/03/2005 | WO2005009400A1 Topical benfotiamine treatments |
| 02/03/2005 | WO2005009398A2 Tetracyclic benzamide derivatives and methods of use thereof |
| 02/03/2005 | WO2005009392A2 Dihydropyrimidone inhibitors of calcium channel function |
| 02/03/2005 | WO2005009391A2 Antibiotic compound |
| 02/03/2005 | WO2005009389A2 Anaplastic lymphoma kinase modulators and methods of use |
| 02/03/2005 | WO2005009388A2 Antiglucocorticoids for the treatment of catatonia |
| 02/03/2005 | WO2005009384A2 Egfr tyrosine kinase inhibitors |
| 02/03/2005 | WO2005009383A2 Methods of treatment with lxr agonists |
| 02/03/2005 | WO2005009382A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 02/03/2005 | WO2005009381A2 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 02/03/2005 | WO2005009377A2 Novel oral bioavailable prodrugs |
| 02/03/2005 | WO2005009373A2 Tyrosine kinase inhibitors |
| 02/03/2005 | WO2005009370A2 Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 02/03/2005 | WO2005009367A2 Treatment of diseases with kinase inhibitors |
| 02/03/2005 | WO2005009362A2 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | WO2005009361A2 Method of treating hit patients with argatroban |
| 02/03/2005 | WO2005009354A2 Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury |
| 02/03/2005 | WO2005009352A2 Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/03/2005 | WO2005009349A2 Composition and method for treating neurological disorders |
| 02/03/2005 | WO2005009348A2 Substituted purine derivatives |
| 02/03/2005 | WO2005009346A2 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| 02/03/2005 | WO2005009345A2 2-desmethyl ansamycin compounds |
| 02/03/2005 | WO2005009344A2 Acylated amino acid amidyl pyrazoles and related compounds |
| 02/03/2005 | WO2005009343A2 A1 adenosine receptor antogonists |
| 02/03/2005 | WO2005009342A2 Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| 02/03/2005 | WO2005009340A2 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
| 02/03/2005 | WO2005009338A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | WO2005009334A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 02/03/2005 | WO2005009331A2 Use of a cosmetic or pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins |
| 02/03/2005 | WO2005009330A2 Method of obtaining inhibitors of type ii dehydroquinase enzyme and precursors thereof |
| 02/03/2005 | WO2005009322A2 Delivery system for topical medications |
| 02/03/2005 | WO2005009207A2 Methods for delaying or inducing labor |
| 02/03/2005 | WO2005009144A1 Pulverulent phytosterol formulations |
| 02/03/2005 | WO2005009135A1 Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| 02/03/2005 | WO2005009129A1 1-n-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases |
| 02/03/2005 | WO2005009124A2 Environmentally safe fungicides |
| 02/03/2005 | WO2005002592A3 Stable oral compositions of azithromycin monohydrate |
| 02/03/2005 | WO2004108867A3 Cyclohexene carboamides and carbothioamides |
| 02/03/2005 | WO2004106307A3 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
| 02/03/2005 | WO2004106279A3 CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST |
| 02/03/2005 | WO2004100863A3 Composition for preventing and treatment of asthma comprising alpha-lipoic acid as an effective component |
| 02/03/2005 | WO2004098599A3 Proton pump inhibitors for the treatment of lower abdominal disorders |
| 02/03/2005 | WO2004098568A3 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| 02/03/2005 | WO2004098527A3 Methods of treating neuralgic pain |
| 02/03/2005 | WO2004096829A3 Novel method and intermediates for the preparation of 19-nor-steroids-17-halogen compounds |
| 02/03/2005 | WO2004094369A3 Stabilized derivatives of ascorbic acid |
| 02/03/2005 | WO2004093854A3 Antineoplastic combinations |
| 02/03/2005 | WO2004091516A3 Methods for controlling the proliferation of cells |
| 02/03/2005 | WO2004091278A3 Gabapentin compositions |
| 02/03/2005 | WO2004089333A3 A stable benzimidazole formulation |
| 02/03/2005 | WO2004087202A3 Pharmaceutical composition comprising a macrolide immunomodulator |
| 02/03/2005 | WO2004087101A3 Oral formulations of cladribine |
| 02/03/2005 | WO2004085457A3 17beta-hydroxysteroid dehydrogenase inhibitors |
| 02/03/2005 | WO2004078122A3 Invisible patch for active agnet controlled delivery |
| 02/03/2005 | WO2004075840A3 Selective non-steroidal glucocorticoid receptor modulators |
| 02/03/2005 | WO2004072102A3 Benzene acetamide compounds useful as serine protease inhibitors |
| 02/03/2005 | WO2004071425A3 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| 02/03/2005 | WO2004069203A3 Oral compositions of fenretinide having increased bioavailability and methods of using the same |
| 02/03/2005 | WO2004064755A3 Methods for inhibiting proteasome |
| 02/03/2005 | WO2004052299B1 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid |
| 02/03/2005 | WO2004048431A3 Polyphosphazene immunocstimulants |
| 02/03/2005 | WO2004047872A3 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 02/03/2005 | WO2004042020A3 Methods for treatment of thiol-containing compound deficient conditions |
| 02/03/2005 | WO2004041208A3 Controlled absorption of mixed thyroyd hormone formulations |
| 02/03/2005 | WO2004041165A3 Compounds for the treatment of metabolic disorders |
| 02/03/2005 | WO2004024089A3 Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| 02/03/2005 | WO2004009083A8 Antitumor compound and therapeutic uses thereof |
| 02/03/2005 | WO2004002416A3 Methods and materials for treating human papillomavirus infections |